Theriva Biologics announced that the THERICEL project has been awarded funding of EUR 2.28M from the National Knowledge Transfer Program of the Spanish government’s Ministry of Science, Innovation & Universities to support a collaboration between the Company and the Universitat Autonoma de Barcelona, UAB, to advance the Company’s suspension cell platform for the clinical manufacture of adenovirus- and adeno-associated virus, AAV, therapies. Under the award, Theriva will receive a loan of EUR 1.33M as a lump sum payment in Q4 2024 which shall be repaid over 7 years commencing three years from the date of award and UAB will receive a grant of EUR 0.95 million dedicated to the THERICEL project and paid in annual installments over the next 3 years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program
- Theriva Biologics files to sell 2.17M shares of common stock, warrants
- Theriva Biologics (TOVX) Is Making Noise With a Promising Pipeline
- Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested
- Theriva Biologics Announces Reverse Stock Split